In summary, targeting the apoptosis pathway by inhibiting Bcl-2 family proteins with VTX in combination with established drugs in the treatment of leukemia is a highly promising strategy to improve survival and reduce treatment-related toxicities for a specific subgroup of AML or ALL pediatric patients. Here, BCL2 is linked to acute lymphoblastic leukemia.